871019-29-3Relevant academic research and scientific papers
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase
Barlaam, Bernard,Ballard, Peter,Bradbury, Robert H.,Ducray, Richard,Germain, Herve,Hickinson, D. Mark,Hudson, Kevin,Kettle, Jason G.,Klinowska, Teresa,Magnien, Francoise,Ogilvie, Donald J.,Olivier, Annie,Pearson, Stuart E.,Scott, James S.,Suleman, Abid,Trigwell, Cath B.,Vautier, Michel,Whittaker, Robin D.,Wood, Robin
, p. 674 - 678 (2008/09/16)
Starting from initial lead 1 containing a basic 5-substituent, optimisation of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compounds 19 and 21 inhibited phosphorylation of erbB
QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES
-
Page/Page column 173, (2010/02/15)
The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
